{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:08:52Z","timestamp":1791493732798,"version":"4.3.4"},"reference-count":19,"publisher":"International Heart Journal (Japanese Heart Journal)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. Heart J."],"published-print":{"date-parts":[[2019,1,31]]},"DOI":"10.1536\/ihj.17-688","type":"journal-article","created":{"date-parts":[[2018,11,19]],"date-time":"2018-11-19T17:21:24Z","timestamp":1542648084000},"page":"208-214","source":"Crossref","is-referenced-by-count":7,"title":["Long-Term Effects of Enzyme Replacement Therapy for Anderson-Fabry Disease"],"prefix":"10.1536","volume":"60","author":[{"given":"Miki","family":"Tsujiuchi","sequence":"first","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mio","family":"Ebato","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyuki","family":"Maezawa","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Mizukami","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaka","family":"Nogi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Rehabilitation Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoko","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Koto-Toyosu Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Iso","sequence":"additional","affiliation":[{"name":"Showa University Research Institute for Sports and Exercise"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Showa University Fujigaoka Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"437","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Germain DP. Fabry disease. Orphanet J Rare Dis 2010; 5: 30.","DOI":"10.1186\/1750-1172-5-30"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Yousef Z, Elliott PM, Cecchi F, <i>et al<\/i>. Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis. Eur Heart J 2013; 34: 802-8.","DOI":"10.1093\/eurheartj\/ehs166"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Patel MR, Cecchi F, Cizmarik M, <i>et al<\/i>. Cardiovascular events in patients with fabry disease natural history data from the fabry registry. J Am Coll Cardiol 2011; 57: 1093-9.","DOI":"10.1016\/j.jacc.2010.11.018"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Oder D, Nordbeck P, Wanner C. Long Term Treatment with Enzyme Replacement Therapy in Patients with Fabry Disease. Nephron 2016; 134: 30-6.","DOI":"10.1159\/000448968"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Vedder AC, Breunig F, Donker-Koopman WE, <i>et al<\/i>. Treatment of Fabry disease with different dosing regimens of agalsidase: effects on antibody formation and GL-3. Mol Genet Metab 2008; 94: 319-25.","DOI":"10.1016\/j.ymgme.2008.03.003"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Germain DP, Charrow J, Desnick RJ, <i>et al<\/i>. Ten-year outcome of enzyme replacement therapy with agalsidase beta in patients with Fabry disease. J Med Genet 2015; 52: 353-8.","DOI":"10.1136\/jmedgenet-2014-102797"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Beck M, Hughes D, Kampmann C, <i>et al<\/i>. Long-term effectiveness of agalsidase alfa enzyme replacement in Fabry disease: A Fabry Outcome Survey analysis. Mol Genet Metab Rep 2015; 3: 21-7.","DOI":"10.1016\/j.ymgmr.2015.02.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Ortiz A, Abiose A, Bichet DG, <i>et al<\/i>. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase beta: data from the Fabry Registry. J Med Genet 2016; 53: 495-502.","DOI":"10.1136\/jmedgenet-2015-103486"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Citro V, Cammisa M, Liguori L, <i>et al<\/i>. The Large Phenotypic Spectrum of Fabry Disease Requires Graduated Diagnosis and Personalized Therapy: A Meta-Analysis Can Help to Differentiate Missense Mutations. Int J Mol Sci 2016; 17.","DOI":"10.3390\/ijms17122010"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Wakakuri H, Nakamura S, Utsumi K, Shimizu W, Yasutake M. Novel alpha-Galactosidase A Mutation (K391E) in a Young Woman With Severe Cardiac and Renal Manifestations of Fabry Disease. Int Heart J 2016; 57: 637-9.","DOI":"10.1536\/ihj.15-475"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Sheppard MN, Cane P, Florio R, <i>et al<\/i>. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy. Cardiovasc Pathol 2010; 19: 293-301.","DOI":"10.1016\/j.carpath.2009.05.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kampmann C, Perrin A, Beck M. Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years&apos; treatment. Orphanet J Rare Dis 2015; 10: 125.","DOI":"10.1186\/s13023-015-0338-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Biegstraaten M, Arngrimsson R, Barbey F, <i>et al<\/i>. Recommendations for initiation and cessation of enzyme replacement therapy in patients with Fabry disease: the European Fabry Working Group consensus document. Orphanet J Rare Dis 2015; 10: 36.","DOI":"10.1186\/s13023-015-0253-6"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Sado DM, White SK, Piechnik SK, <i>et al<\/i>. Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping. Circ Cardiovasc Imaging 2013; 6: 392-8.","DOI":"10.1161\/CIRCIMAGING.112.000070"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Wilcox WR, Linthorst GE, Germain DP, <i>et al<\/i>. Anti-alpha-galactosidase A antibody response to agalsidase beta treatment: data from the Fabry Registry. Mol Genet Metab 2012; 105: 443-9.","DOI":"10.1016\/j.ymgme.2011.12.006"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Fellgiebel A, Gartenschlager M, Wildberger K, Scheurich A, Desnick RJ, Sims K. Enzyme replacement therapy stabilized white matter lesion progression in Fabry disease. Cerebrovasc Dis 2014; 38: 448-56.","DOI":"10.1159\/000369293"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Altarescu GM, Goldfarb LG, Park KY, <i>et al<\/i>. Identification of fifteen novel mutations and genotype-phenotype relationship in Fabry disease. Clin Genet 2001; 60: 46-51.","DOI":"10.1034\/j.1399-0004.2001.600107.x"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Rigoldi M, Concolino D, Morrone A, <i>et al<\/i>. Intrafamilial phenotypic variability in four families with Anderson-Fabry disease. Clin Genet 2014; 86: 258-63.","DOI":"10.1111\/cge.12261"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Altarescu G, Moore DF, Schiffmann R. Effect of genetic modifiers on cerebral lesions in Fabry disease. Neurology 2005; 64: 2148-50.","DOI":"10.1212\/01.WNL.0000166000.24321.4F"}],"container-title":["International Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/1\/60_17-688\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,26]],"date-time":"2019-01-26T21:44:43Z","timestamp":1548539083000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/ihj\/60\/1\/60_17-688\/_article"}},"subtitle":["Differences in Three Siblings with the Same Genotype"],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1536\/ihj.17-688","relation":{},"ISSN":["1349-2365","1349-3299"],"issn-type":[{"value":"1349-2365","type":"print"},{"value":"1349-3299","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]}}}